Novartis expands development programs for NASH through clinical collaboration with Allergan
(Thomson Reuters ONE) -
Novartis International AG /
Novartis expands development programs for NASH through clinical collaboration
with Allergan
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist
and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic
fatty liver disease
* There are currently no approved treatments for NASH, which is a major cause
of liver disease worldwide and the leading cause of liver transplants for
people under 50 in the US[1]
* Novartis has a rapidly growing development portfolio in NASH, investigating
single and combination therapies across all stages of the disease
Basel, April 18, 2017 - Novartis announced today that it has entered into a
clinical trial agreement with Allergan plc to conduct a Phase IIb study,
involving the combination of a Novartis FXR agonist and Allergan's cenicriviroc
(CVC) for the treatment of non-alcoholic steatohepatitis (NASH). The financial
details of this transaction are not disclosed.
NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), which
is characterized by the accumulation of fat in the liver, inflammation and
fibrosis (scarring), and can eventually lead to cirrhosis and liver failure.
NASH is a major cause of liver disease worldwide and the leading cause of liver
transplants for people under 50 in the US[1]. There are currently no approved
treatments for NASH.
"Our clinical collaboration with Allergan expands our development programs for
NASH, bringing together science and expertise to investigate a potential new
combination therapy in an effort to make a positive change for people living
with this condition," said Vas Narasimhan, Global Head, Drug Development and
Chief Medical Officer, Novartis. "We believe that collaboration is key to
developing the best possible treatments that are urgently needed for NASH
patients."
CVC is a once-daily, oral, Phase III ready potent immunomodulator that blocks
two chemokine receptors, CCR2 and CCR5, which are involved in inflammatory and
fibrogenic pathways. In the Phase IIb CENTAUR study, CVC demonstrated a
clinically meaningful improvement in fibrosis of at least one stage without
worsening of NASH after one year of treatment, which is one of only two
approvable Phase III endpoints. With its unique Mechanism of Action (MOA) and
its favorable safety profile, CVC represents an ideal candidate to become the
backbone of NASH multi-therapy treatment. CVC has been granted Fast Track
designation by the US Food and Drug Administration (FDA) in patients with NASH
and liver fibrosis.
Novartis is developing Farnesoid X receptor (FXR) agonists for the treatment of
chronic liver diseases, including NASH. The most advanced investigational
compound is a potent, non-bile acid FXR agonist, which recently received Fast
Track designation from the FDA and is in a Phase II clinical trial. As part of
this agreement, Novartis and Allergan will conduct a Phase IIb clinical trial to
assess the safety, efficacy and tolerability of a combination therapy for NASH.
In December 2016, Novartis announced an exclusive option for a collaboration and
license agreement with Conatus Pharmaceuticals Inc. to jointly develop emricasan
for NASH. Emricasan is an investigational, first-in-class, oral, pan-caspase
inhibitor and our agreement with Conatus has the potential to expand treatment
options for people in various stages of NASH, including those with the advanced
form of the disease, NASH cirrhosis. Both collaborations with Conatus and
Allergan continue to support the growing Novartis portfolio to develop new
therapies in chronic liver diseases, including NASH.
About Novartis FXR agonists
Novartis scientists began to develop leads for the FXR agonism program in 2007.
Through this effort, several non-bile acid FXR agonists have been identified and
pre-clinical data demonstrates that these compounds are very selective with
differentiated biological profiles. FXR agonists have been shown to address
three of the most important aspects of NASH progression by reducing fat,
inflammation and fibrosis in the liver. First-in-human studies have continued to
support their differentiated profiles and their potential for further
development. Two Novartis FXR agonists are now in worldwide clinical studies in
NASH patients and both have received Fast Track designation status from the FDA.
About Non-Alcoholic Steatohepatitis (NASH)
NASH is a chronic, progressive form of non-alcoholic fatty liver disease. It is
a leading cause of liver disease worldwide and it is estimated to affect 3% to
5% of the US population alone[2]. As fat builds up in the liver, it triggers a
vicious cycle of chronic inflammation and liver scarring called fibrosis. Over
time, liver inflammation and fibrosis may progress to cirrhosis, which can lead
to liver failure and, barring a transplant, death. NASH is expected to be the
principal cause of liver transplantation in the US by 2020[3] and is currently
the leading cause of liver transplants for people under 50 in the US[1].
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "expands," "development programs," "to evaluate," "rapidly
growing," "investigating," "to investigate," "positive change," "believe," "Fast
Track designation," "investigational," "will," "option," "growing," "potential,"
"may," "expected," or similar terms, or by express or implied discussions
regarding potential marketing approvals for cenicriviroc, the FXR agonists being
developed internally by Novartis, and emricasan, either as single agents or in
combination, or regarding potential future revenues from these products. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that the necessary government approvals for the
transaction with Allergan or exercise of the option with Conatus will be
obtained in any particular time frame, or at all. Neither can there be any
guarantee that any other closing conditions for the transactions with Allergan
or Conatus will be met in any particular time frame, or at all. Nor can there be
any guarantee that the collaborations with Allergan or Conatus will achieve any
of their intended goals and objectives, or in any particular time frame. Nor can
there be any guarantee that cenicriviroc or the FXR agonists being developed
internally by Novartis, or emricaasan, either as single agents or in
combination, will be submitted or approved for sale in any market, or at any
particular time. Nor can there be any guarantee that any or all of these
products will be commercially successful in the future. Management's
expectations regarding each of the transactions, cenicriviroc, emricasan, and
the FXR agonists being developed internally by Novartis could be affected by,
among other things, a failure to obtain necessary government approvals for the
transactions with Allergan and Conatus, or delays in obtaining such approvals,
and the potential that any other closing conditions for the transaction may not
be met; the uncertainties inherent in research and development, including
clinical trial results and additional analysis of existing clinical data;
regulatory actions or delays or government regulation generally; the company's
ability to obtain or maintain proprietary intellectual property protection;
general economic and industry conditions; global trends toward health care cost
containment, including ongoing pricing pressures; safety, quality or
manufacturing issues, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1.] Banini BA, et al. Abstract #46. Presented at: American College of
Gastroenterology Annual Scientific Meeting; Oct. 14-19, 2016; Las Vegas, NV.
[2.] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and
natural history of non-alcoholic fatty liver disease and non-alcoholic
steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85.
[3.] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA.
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis
in the United States. Gastroenterology; 2011:141 (4):e22-e23.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Bhavin Vaid
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8175 (direct)
+41 79 593 4202 (mobile) +41 79 792 7510 (mobile)
eric.althoff(at)novartis.com bhavin.vaid(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2096284/793153.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.04.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 536605
Anzahl Zeichen: 12550
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis expands development programs for NASH through clinical collaboration with Allergan"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
